Niagen Bioscience's (NAGE) Hold (C) Rating Reiterated at Weiss Ratings

Key Points

• Niagen Bioscience's stock has a "hold (c)" rating reiterated by Weiss Ratings, while Canaccord Genuity increased its target price from $13.00 to $16.00 and gave it a "buy" rating.
• The company recently reported a quarterly earnings per share of $0.04, surpassing estimates, and generated revenue of $31.12 million, exceeding the consensus estimate of $28.55 million.
• Shares of Niagen Bioscience opened at $7.43, with a market cap of $592.54 million and a consensus target price of $13.42, indicating potential upside based on analyst ratings.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report)'s stock had its "hold (c)" rating reiterated by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

NAGE has been the topic of several other research reports. Canaccord Genuity Group lifted their target price on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. Finally, HC Wainwright lifted their target price on shares of Niagen Bioscience from $11.00 to $12.00 and gave the company a "buy" rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.42.

Niagen Bioscience Stock Up 3.5%

Shares of NASDAQ:NAGE opened at $7.43 on Wednesday. The company has a market cap of $592.54 million, a price-to-earnings ratio of 35.38 and a beta of 2.13. The firm's 50-day simple moving average is $9.43 and its 200-day simple moving average is $9.57. Niagen Bioscience has a fifty-two week low of $3.18 and a fifty-two week high of $14.69.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The business had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%.

Hedge Funds Weigh In On Niagen Bioscience

An institutional investor recently bought a new position in Niagen Bioscience stock. Silverberg Bernstein Capital Management LLC bought a new position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 125,262 shares of the company's stock, valued at approximately $1,169,000. Silverberg Bernstein Capital Management LLC owned about 0.16% of Niagen Bioscience at the end of the most recent quarter. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.